Core Insights - The report emphasizes the importance of innovation in the pharmaceutical and biotechnology industry, particularly focusing on the overseas expansion of innovative drugs and the adoption of new technologies [1][4]. - The investment rating for the sector is maintained at "outperform the market" [2]. Group 1: Market Overview and Trends - The overseas market for innovative drugs and the CXO industry is expected to perform exceptionally well in 2025, driven by continuous business development (BD) activities, strong clinical data, and supportive policies [4]. - The domestic supply and demand remain stable, with a shift in payment systems favoring innovation. National health expenditure increased by 4.7% year-on-year in the first 11 months of 2025, marking a recovery after two years of decline [4]. - The report highlights the significant growth potential in new drug forms such as dual antibodies and small nucleic acid drugs, as well as innovations in AI healthcare and brain-machine interfaces [4]. Group 2: Investment Recommendations - The report recommends focusing on companies with global competitiveness and differentiated innovation capabilities, as well as domestic CXO leaders with high barriers in cost control, technology accumulation, and production capacity [4]. - Recommended stocks include Mindray Medical, WuXi AppTec, Kelaiying, Aier Eye Hospital, and several others, with specific mention of H-shares like Kelun-Bio and CanSino Biologics [4][5]. Group 3: Financial Performance and Projections - The report provides a detailed strategy portfolio for 2026, listing companies along with their projected net profits and price-to-earnings (PE) ratios, indicating a generally positive outlook for the sector [5]. - The pharmaceutical sector's overall performance in 2025 was strong, with significant gains in sub-sectors such as medical services and chemical pharmaceuticals, driven by BD collaborations and clinical data releases [12][23]. Group 4: Fund Holdings and Market Sentiment - As of Q4 2025, the net asset value of pharmaceutical funds decreased by 9.0%, with a notable shift where passive funds surpassed active funds for the first time since 2019 [25][32]. - The report indicates a decline in the proportion of pharmaceutical holdings in both active and non-pharmaceutical funds, with a concentration in chemical preparations and other biological products [32][40].

证券研究报告 | 2026年01月26日 策略周报 融资交易情绪边际降温——1 月第 3 周立体投资策略周报 核心结论：①1 月第 3 周，资金入市合计净流出 1705 亿元，前一周流入 49 亿元。②短期情绪指标处于 05 年以来高位，长期情绪指标处于 05 年以来中 低位。③从行业角度看，以成交额占比为例，过去一周半导体、电子、国防 军工等热度较高。 1 月第 2 周，资金入市合计净流出 1705 亿元，前一周流入 49 亿元。资金流 入方面，融资余额减少 83 亿元，公募基金发行增加 393 亿元，ETF 净赎回 1623 亿元，北上资金估算净流出 93 亿元；资金流出方面，IPO 融资规模 46 亿元，产业资本净减持 118 亿元，交易费用 136 亿元。 短期情绪指标处于 05 年以来高位。短期情绪指标主要看换手率和融资交易 占比，最近一周换手率（年化）为 557%，当前处在历史上由低到高 87%的分 位；最近一周融资交易占比为 9.88%，当前处在历史上由低到高 73%的分位。 长期情绪指标处于 05 年以来中低位。长期情绪指标主要看大类资产比价， 一看价格对比，最近一周 A 股风险溢价（全部 A ...

Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [1][6][22] Core Viewpoints - The management's recent share buybacks demonstrate confidence in the company's future and stock price [3][4] - The company's new product series, PUCKY and Starry People, have shown strong demand, with sold-out status on official platforms and significant price premiums on secondary markets, indicating potential for IP value enhancement during the upcoming holiday season [3][5] - The company is expected to see substantial profit growth, with projected net profits for 2025-2027 at 120.2 billion, 170.5 billion, and 208.9 billion respectively, reflecting year-on-year growth of 284.4%, 41.9%, and 22.6% [3][10][15] Summary by Relevant Sections Share Buyback - The company announced a buyback of 500,000 shares at a price of 192.97 yuan per share and the cancellation of 1.4 million shares at 179.60 yuan per share, indicating a total buyback amount of approximately 347.9 million yuan [2][5] Product Performance - Recent trends show that the PUCKY and Starry People series have sold out on official websites, with price premiums on secondary markets ranging from 2-3 times for hidden versions and 70-200% for regular versions, suggesting strong market demand [3][5][9] Financial Projections - The company has revised its profit forecasts, expecting revenues of 356.2 billion, 512.5 billion, and 634.5 billion for 2025-2027, with corresponding year-on-year growth rates of 173.2%, 43.9%, and 23.8% [10][19] - The gross margin is projected to exceed 70% in the first half of 2025, with a steady gross margin of around 71% expected through 2027 [12][19]

Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [1][6][3] Core Views - The management's recent share buybacks demonstrate confidence in the company's future and stock price [4][3] - The company's new product series, PUCKY and Starry People, have sold out on official platforms and are trading at significant premiums on secondary markets, indicating strong IP potential [3][5] - The company is expected to see substantial profit growth, with net profits projected to reach 12.02 billion, 17.05 billion, and 20.89 billion for 2025-2027, reflecting year-on-year growth of 284.4%, 41.9%, and 22.6% respectively [3][10] Summary by Sections Share Buyback - The company announced a buyback of 500,000 shares at a price of 192.97 yuan per share and the cancellation of 1.4 million shares at 179.60 yuan per share, showing a total buyback of 3.47 billion yuan for 1.9 million shares [2][5] Product Performance - Recent trends show that the PUCKY and Starry People series have sold out on the official website, with hidden versions trading at premiums of 2-3 times and regular versions at 70-200% premiums [5][9] Financial Projections - The company has revised its profit forecasts, expecting net profits of 12.02 billion, 17.05 billion, and 20.89 billion for 2025-2027, with corresponding P/E ratios of 23, 16, and 13 [3][10] - Revenue projections for 2025-2027 are set at 35.62 billion, 51.25 billion, and 63.45 billion, with growth rates of 173.2%, 43.9%, and 23.8% respectively [10][19]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown weaker performance compared to the overall market, with a TTM P/E ratio of 38.51x, which is at the 84.35th percentile of the past five years [1][37]. - The report highlights the importance of the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO field, and suggests that the sector's valuation is expected to recover [41]. - The report recommends focusing on innovative drugs and the associated industry chain, with a notable mention of the upcoming JPM conference and the clinical progress of innovative drugs overseas [41][42]. Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the biotechnology sector declined by 0.39%. The medical services sector was the worst performer, dropping by 2.17% [1][32]. - The report notes that the largest sub-sectors by holding percentage are chemical preparations (37.5%) and other biological products (20.8%) [19]. Fund Holdings Analysis - As of Q4 2025, the total net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11]. - The report indicates that the pharmaceutical holdings of all funds accounted for 7.97%, down by 1.71 percentage points [16]. Key Company Earnings Forecasts - The report provides earnings forecasts for several key companies, all rated "Outperform": - Mindray Medical (300760.SZ): 2024A net profit of 11.67 billion [4] - WuXi AppTec (603259.SH): 2024A net profit of 9.35 billion [4] - Aier Eye Hospital (300015.SZ): 2024A net profit of 3.56 billion [4] - New Industry (300832.SZ): 2024A net profit of 1.83 billion [4] - Huatai Medical (688617.SH): 2024A net profit of 670 million [4] Investment Strategy - The report recommends a portfolio of stocks including Mindray Medical, WuXi AppTec, Aier Eye Hospital, and others, focusing on companies with strong growth potential in the innovative drug sector [42][43].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market, with a 0.39% decline in the biopharmaceutical sector compared to a 1.17% increase in the total A-share market [32] - The TTM price-to-earnings ratio for the pharmaceutical sector is 38.51x, which is at the 84.35th percentile of the historical valuation over the past five years [32][37] - The report highlights a shift in fund holdings, with a decrease in the proportion of pharmaceutical holdings in both pharmaceutical and non-pharmaceutical funds [11][16] Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the Shanghai and Shenzhen 300 index decreased by 0.62% [32] - The biopharmaceutical sector's performance was weaker than the overall market, with specific declines in chemical pharmaceuticals (-1.11%) and medical services (-2.17%) [32] Fund Holdings Analysis - As of Q4 2025, the net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11] - The proportion of pharmaceutical holdings in all funds was 7.97%, down 1.71 percentage points [16] - The largest sub-sectors by holdings were chemical preparations (37.5%) and other biological products (20.8%) [19] Company Earnings Forecasts and Ratings - Key companies such as Mindray Medical (237 billion market cap, "Outperform" rating) and WuXi AppTec (293.6 billion market cap, "Outperform" rating) are highlighted for their strong earnings forecasts [4] - The report lists several companies with projected earnings growth, including Aier Eye Hospital and New Industry, both rated "Outperform" [4] Investment Strategy - The report recommends focusing on innovative drugs and the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO space [41] - A portfolio of recommended stocks includes Mindray Medical, WuXi AppTec, and Aier Eye Hospital, among others [42][43]

证券研究报告 | 2026年01月26日 美元债双周报（26 年第 4 周） 弱于大市 地缘风险与财政隐忧下美债利率升至半年新高 美国 11 月 PCE 物价指数符合预期，通胀温和且支出稳健。1 月 22 日美国经 济分析局发布的 11 月 PCE 报告显示，PCE 物价指数同比上涨 2.8%，环 比上涨 0.2%，均与市场预期一致，反映通胀温和运行。剔除食品和能源 后的核心 PCE 同比亦上涨 2.8%，环比增长 0.2%，同样符合预期。报告 同时指出，美国个人支出在 11 月保持稳健增长，显示消费者支出依然 是经济增长的重要支撑，不过储蓄率进一步下滑，这或对中长期消费动 力构成一定压力。核心 PCE 维持在较高水平但未显著超预期，表明通胀 压力虽有所缓解但仍高于美联储 2%的长期目标。 2025 年第三季度美国实际 GDP 终值年化季环比增速上修至 4.4%，略超预期， 达两年最快。增长由出口增强、库存变化负面影响减小及消费韧性驱动， 表明经济扩张动力强。同期核心 PCE 终值维持在 2.9%，高于美联储 2% 目标，通胀具粘性。强劲增长与稳健就业使市场预计美联储 1 月将按兵 不动。CME 美联储观察工 ...

证券研究报告 | 2026年01月26日 德力佳（603092.SH） 公司产能持续扩张，夯实成长前景 公司研究·公司快评 电力设备·风电设备 投资评级：优于大市（维持） 证券分析师： 王蔚祺 010-88005313 wangweiqi2@guosen.com.cn 执证编码：S0980520080003 证券分析师： 王晓声 010-88005231 wangxiaosheng@guosen.com.cn 执证编码：S0980523050002 联系人： 王喆萱 wangzhexuan@guosen.com.cn 事项： 2026 年 1 月 25 日，公司与无锡宛山湖产业发展有限公司、羊尖镇人民政府签署《德力佳 10 兆瓦以上风电 用变速箱研发制造项目投资合作协议》，推进公司风电齿轮箱产能扩充。该项目主要面向陆上及海上大功 率风电机型（10 兆瓦以上）的齿轮箱配套需求，总投资 50 亿元（初期预投 20 亿），资金来源为公司自有 资金和银行贷款，预计 2026 年 7 月开工。 国信电新观点：公司顺应风电行业"大型化、海上化"发展趋势，新建 10MW 以上风电齿轮箱项目以匹配 陆上及海上风电大功率机型齿 ...

证券研究报告 | 2026年01月26日 酒店行业深度专题 优于大市 新周期开启，头部玩家重塑成长价值 国内酒店龙头市值从百亿级发展至今呈现非线性增长特征，周期拐点预期与 资本整合是跃升的核心驱动力，长期看规模与效益。复盘酒店估值遵循"周 期为锚、成长性为助推器、中线看规模与效益"三维体系：宏观供需错配决 定估值拐点（如2016-2018 年周期上行阶段估值提升至40-50x，而2024-2025 年供给回补周期下行阶段估值回落至 15-20x），中观结构升级与模式升级放 大波动（如华住在 2016-2018 年中端升级期的估值放大），公司自身经营周 期提供个股阿尔法展现出逆势估值提升（如亚朵在 2024 年行业下行期凭借 零售业务超预期推动估值从 15x 修复至 23x）；长期视角对比海外成熟龙头 各项指标，龙头规模成长、单房经营效率、股东回报构成稳态估值差异关键。 当前周期底部行业分化加大，供需再平衡阶段龙头 RevPAR 有望触底回升。 （一）供给侧：行业稳定现金流特征使得总供给受其他物业切入增量边际扰 动，但开店与投资回报需求平衡下行业有望进入新常态增长阶段，以龙头为 例储备店较高位呈现回落；此前国内 ...

证券研究报告 | 2026年01月26日 美元债双周报（26 年第 4 周） 弱于大市 地缘风险与财政隐忧下美债利率升至半年新高 美国 11 月 PCE 物价指数符合预期，通胀温和且支出稳健。1 月 22 日美国经 济分析局发布的 11 月 PCE 报告显示，PCE 物价指数同比上涨 2.8%，环 比上涨 0.2%，均与市场预期一致，反映通胀温和运行。剔除食品和能源 后的核心 PCE 同比亦上涨 2.8%，环比增长 0.2%，同样符合预期。报告 同时指出，美国个人支出在 11 月保持稳健增长，显示消费者支出依然 是经济增长的重要支撑，不过储蓄率进一步下滑，这或对中长期消费动 力构成一定压力。核心 PCE 维持在较高水平但未显著超预期，表明通胀 压力虽有所缓解但仍高于美联储 2%的长期目标。 风险提示：美国经济和货币、财政、贸易政策的不确定性。 核心观点 行业研究·海外市场专题 美股 弱于大市·维持 | 证券分析师：王学恒 | 证券分析师：徐祯霆 | | --- | --- | | 010-88005382 | 010-88005494 | | wangxueh@guosen.com.cn | xuzhenti ...